GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » FCF Margin %

Cleo Diagnostics (ASX:COV) FCF Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cleo Diagnostics's Free Cash Flow for the six months ended in Dec. 2023 was A$-1.30 Mil. Cleo Diagnostics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Cleo Diagnostics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Cleo Diagnostics's current FCF Yield % is -8.10%.

The historical rank and industry rank for Cleo Diagnostics's FCF Margin % or its related term are showing as below:


ASX:COV's FCF Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -7.45
* Ranked among companies with meaningful FCF Margin % only.


Cleo Diagnostics FCF Margin % Historical Data

The historical data trend for Cleo Diagnostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics FCF Margin % Chart

Cleo Diagnostics Annual Data
Trend Jun23
FCF Margin %
-

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23
FCF Margin % - - -

Competitive Comparison of Cleo Diagnostics's FCF Margin %

For the Medical Devices subindustry, Cleo Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cleo Diagnostics's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's FCF Margin % falls into.



Cleo Diagnostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cleo Diagnostics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-1.024/0
= %

Cleo Diagnostics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-1.298/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleo Diagnostics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics (ASX:COV) Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines